Actinium presents updated survival data from Phase 2b trial of Actimab-A

Actinium Pharmaceuticals highlighted updated survival data from its Phase 1b trial evaluating Actimab-A in combination with the salvage chemotherapy CLAG-M in patients with high-risk relapsed or refractory acute myeloid leukemia and new preclinical data with Actimab-A in combination with FLT3 inhibitors at the Society of Hematologic Oncology, SOHO, 2023 Annual Meeting. In addition, results of the completed and positive Phase 3 SIERRA trial of Iomab-B were presented. SOHO Data Highlights: Updated Actimab-A + CLAG-M Phase 1b Study Results: 30-month median Overall Survival in patients with prior venetoclax treatment who proceeded to bone marrow transplant following Actimab-A + CLAG-M; 24-month median OS in all patients who proceeded to BMT following Actimab-A + CLAG-M; 100% measurable residual disease negativity in patients with prior venetoclax treatment and 75% MRD negativity in all patients; 83% of patients had high-risk r/r AML; 57% of patients (13/23) received prior treatment with venetoclax; Patients who relapse after venetoclax treatment have poor survival outcomes with a limited percentage of patients proceeding to BMT. Poster Title: Sequential Salvage Chemotherapy and Lintuzumab-Ac225 in Relapsed/Refractory AML Results in Deep Responses and Prolonged Survival in Adverse Risk Acute Myeloid Leukemia and in AML Patients that Received Prior Venetoclax Therapy. Actimab-A Program Expansion into FLT3 Mutant AML: actimab-A shown to have single-agent cytotoxic activity against FLT3 mutant AML cell lines; The addition of Actimab-A enhances the anti-leukemic activity of FLT3 inhibition of approved FLT3 inhibitors gilteritinib and midostaurin in vitro; FLT3 mutations are associated with aggressive disease with poor outcomes and occur in approximately 30% of patients, making it one of the most commonly mutated genes in AML; Combinations of Actimab-A with FLT3 inhibitors can potentially be explored under Actinium’s CRADA with the NCI. Poster Title: Antileukemic Activity of Lintuzumab-Ac225 in Preclinical Model of FLT3 Mutant AML